

QR Pharma, Inc. Presents New Data on Posiphen in Alzheimer's and Parkinson's Disease at the 13th AD/PD International Conference

--Posiphen Restores Memory and Learning and Brain Function as well as Gut Motility and Coordination in Mice Models of AD and PD--

Berwyn, Pa., March 16, 2017 — QR Pharma, Inc., a privately held phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer's (AD), Parkinson's (PD) and other neurodegenerative diseases, today announced the presentation at the 13th AD/PD International Conference in Vienna, Austria, "Treating Acute and Chronic Neurodegeneration by Inhibiting Neurotoxic Aggregating Proteins" showing data relating to [its lead clinical product candidate, Posiphen](#). The talk is scheduled for Sunday April 2, 2017 at 13:00.

The presentation highlights studies conducted by investigators from Columbia University characterizing the effects of Posiphen in a transgenic model of AD and from UCSF showing the effects of Posiphen in a transgenic model of PD. Posiphen administered daily orally to transgenic APP/PS1 mice preserved spatial working memory and brain function; while administered daily intraperitoneally to transgenic alpha-synuclein mice it restored gut motility and coordination.

"These are impressive results for Posiphen" commented [Ottavio Arancio, MD, PhD, Professor at Columbia University](#). "The mechanism of action of the compound leading to pleiotropic effects in multiple neurodegenerative conditions is quite novel and very interesting."

"These studies provide further confirmation of the neuroprotective effects of Posiphen," stated [Maria Maccacchini, Ph.D., President and CEO of QR Pharma](#). "They add to a deep data set supporting the unique activity and potentially broad application of Posiphen in chronic as well as acute neurodegenerative conditions."

A full copy of the AD/PD talk entitled, "Treating Acute and Chronic Neurodegeneration by Inhibiting Neurotoxic Aggregating Proteins," is available by visiting the "Scientific Presentations" in the Press Room section of QR Pharma's website at www.qrpharma.com.

About QR Pharma, Inc.

Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders.

QR is currently developing Posiphen as a disease-modifying drug for acute as well as chronic neurodegeneration and BNC for advanced Alzheimer's disease. For more information on QR Pharma, please visit the company's website, www.qrpharma.com

Contact: Maria Maccacchini
Tel: 610-727 3710
Fax: 610 727 4001
maccacchini@qrpharma.com
www.qrpharma.com